UCB prepares for Cimzia filing in axial spondyloarthritis and psoriatic arthritis
This article was originally published in Scrip
Executive Summary
UCB is to make US and EU regulatory submissions for Cimzia (certolizumab pegol) by the end of the year for axial spondyloarthritis (AxSpA) including ankylosing spondylitis (AS), after reporting positive top-line Phase III results for the drug in these indications.